Sjogren's Syndrome
Conditions
Interventions
Experimental: Arm A
ianalumab s.c.(exposure level 1)
Experimental: Arm B
ianalumab s.c.(exposure level 2)
Placebo Comparator: Arm C
placebo
Sponsors
Maruyama Hideki
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Signed informed consent must be obtained prior to participation in the study - Women and men >= 18 years of age - Classification of Sjogren's syndrome according to the ACR/EULAR 2016 criteria - Time since diagnosis of Sjogren's of == 5 within the following 8 domains: constitutional, lymphadenopathy, glandular, articular, cutaneous, renal, hematological and biologic. - Stimulated whole salivary flow (sSF) rate of >= 0.05 mL/min at screening - Ability to communicate well with the Investigator, understand and agree to comply with the requirements of the study - Patients taking hydroxychloroquine (=< 400 mg/day), methotrexate (=<25 mg/week) or azathioprine (=<150 mg/day) alone or in combination, are allowed to continue their medication, and must have been on a stable dose for at least 30 days prior to randomization. - Patients taking systemic corticosteroids have to be on a stable dose of =< 10 mg/day predniso(lo)ne or equivalent for at least 30 days before randomization. - Patients taking - disease-modifying antirheumatic drugs (DMARDs) other than specifically allowed in inclusion criterion #9 or - the following Traditional Chinese Medicines: Total glucoside of peony (TGP) or Tripterium glycosides (TG) must discontinue these medications at least 30 days prior to randomization, except for leflunomide, which has to be discontinued for 8 weeks prior to randomization unless a cholestyramine wash-out has been performed.
Exclusion criteria
Exclusion criteria: - Presence of another autoimmune rheumatic disease that is active and constitutes the principal illness - Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days or until the expected pharmacodynamic effect has returned to baseline, whichever is longer. - Prior treatment with ianalumab - Prior use of a B-cell depleting therapy other than ianalumab within 36 weeks prior to randomization or as long as B-cell count is 10 mg/day - Any one of the following laboratory values at screening: - Hemoglobin levels < 8.0 g/dL - White blood cells (WBC) count < 2.0 x 10E3/microliter - Platelet count < 80 x 10E3/microliter - Absolute neutrophil count(ANC) < 0.8 x 10E3/microliter - Active viral, bacterial or other infections requiring systemic treatment at the time of screening or randomization, or history of recurrent clinically significant infection or of bacterial infections with encapsulated organisms - History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar chemical classes (e.g., mAb of IgG1 class) or to any of the constituents of the study drug formulation(sucrose, L-histidine hydrochloride/ L-histidine, polysorbate 20) - History of major organ, hematopoietic stem cell or bone marrow transplant - Required regular use of medications known to cause dry mouth/eyes as a regular and major side effect, and which have not been on a stable dose for at least 30 days prior to Screening, or any anticipated change in the treatment regimen during the course of the study. - Use of topical ocular prescription medications (excluding artificial tears, gels, lubricants) that have not been on a stable dose for at least 90 days prior to randomization, or any anticipated change in the treatment regimen during the course of the study - Receipt of live/attenuated vaccine within a 4-week period prior to randomization - History of primary or secondary immunodeficiency, including a positive human immunodeficiency virus (HIV) test result - History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer or Sjogren's related lymphoma), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases. - History of sarcoidosis - Any surgical, medical (e.g., uncontrolled hypertension, heart failure or diabetes mellitus), psychiatric or additional physical condition that the Investigator feels may jeopardize the patient in case of participation in this study - Chronic infection with hepatitis B (HBV) or hepatitis C (HCV). Positive serology for hepatitis B surface antigen (HBsAg) excludes the subject. - Evidence of active tuberculosis(TB) infection (after anti-TB treatment, patients with history of or latent TB may become eligible according to national guidelines) - Pregnant or nursing (lactating) women, - Women of child-bearing potential, defined as all women physiologically capable of b
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in EULAR Sjogren Syndrome Disease Activity Index (ESSDAI) score at Week 48 as compared to placebo [ Time Frame: 48 weeks ] Efficacy (Plan A: US and US reference countries and Plan B: EU, other non-US Regions and EU reference | — |
Countries
Argentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Colombia, France, Germany, Greece, Hungary, Iceland, India, Israel, Italy, Japan, Lebanon, Mexico, Peru, Poland, Romania, Russia, Slovakia, South Africa, Spain, Sweden, Taiwan, United Kingdom, United States
Contacts
Public ContactHideki Maruyama
Novartis Pharma. K.K.
Outcome results
None listed